Latest filing published 07 May 2025 for NKGen Biotech, Inc., €2.3M.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 9 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -52.1%Entry US$0.17 · Close at T+365 US$0.08
- -84.7%Entry US$3.40 · Close at T+365 US$0.52
- -86.4%Entry US$3.30 · Close at T+365 US$0.45
- -88.1%Entry US$3.37 · Close at T+365 US$0.40
- -88.1%Entry US$2.93 · Close at T+365 US$0.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Paul Y. Song: trading record in brief
All filings by Paul Y. Song on record concern NKGen Biotech, Inc. Between 21 November 2023 and 5 May 2025, the trades on record add up to 9 filings.
Purchases make up the whole of the open-market record (9 purchases, €2.3M). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2025, the count stands at 1 purchase and no sales.
Half of the purchases are above €275 and half below. Clusters matter here: 8 out of 9 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 9 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 11% of cases, with a median move of -67.6%. They describe history only and say nothing certain about the share price ahead.
The newest entry dates from 7 May 2025: an open-market purchase of €2.3M, in NKGen Biotech, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Paul Y. Song
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,849,725 shares@ US$0.127199.9% of flowCommon StockSEC:0001213900-25-040627:0Canonical exit: 3 Aug 2025 (T+90)
- 76.06 shares@ US$3.290.0% of flowCommon StockSEC:0001209191-23-057748:1Canonical exit: 6 Mar 2024 (T+90)
- 75.3 shares@ US$3.320.0% of flowCommon StockSEC:0001209191-23-057748:0Canonical exit: 5 Mar 2024 (T+90)
- 105.17 shares@ US$3.330.0% of flowCommon StockSEC:0001209191-23-057370:1Canonical exit: 4 Mar 2024 (T+90)
- 162.78 shares@ US$3.070.0% of flowCommon StockSEC:0001209191-23-057370:0Canonical exit: 3 Mar 2024 (T+90)
- 140.4 shares@ US$2.850.0% of flowCommon StockSEC:0001209191-23-056768:1Canonical exit: 25 Feb 2024 (T+90)
- 103.25 shares@ US$2.910.0% of flowCommon StockSEC:0001209191-23-056768:0Canonical exit: 25 Feb 2024 (T+90)
- 52.63 shares@ US$2.850.0% of flowCommon StockSEC:0001209191-23-056523:1Canonical exit: 20 Feb 2024 (T+90)
- 100 shares@ US$2.800.0% of flowCommon StockSEC:0001209191-23-056523:0Canonical exit: 19 Feb 2024 (T+90)
9 of 9 declarations